1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Netherlands >
  5. Clade Therapeutics Acquires Gadeta

M&A Deal Summary

Clade Therapeutics Acquires Gadeta

On October 2, 2023, Clade Therapeutics acquired life science company Gadeta

Acquisition Highlights
  • This is Clade Therapeutics’ 1st transaction in the Life Science sector.
  • This is Clade Therapeutics’ 1st transaction in the Netherlands.

M&A Deal Summary
Date 2023-10-02
Target Gadeta
Sector Life Science
Buyer(s) Clade Therapeutics
Deal Type Add-on Acquisition

Target

Gadeta

Utrecht, Netherlands
Gadeta is a cell therapy company developing innovative treatments based on g/d T cell receptors for targeting solid tumors. The company's platform is focused on discovering and developing novel g/d T cell receptors (TCRs) that can specifically recognize novel cancer-specific surface targets. Gadeta was formed in 2015 and is based in Utrecht, Netherlands.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Clade Therapeutics

Boston, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines. The company provides a robust cellular platform with stem-cell-derived immune cells for the treatment of cancer and autoimmune diseases. Clade Therapeutics is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Netherlands M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal